Latest news from the Science Center, our resident companies and the innovation ecosystem.
July 13, 2017 | Press Releases
Christopher J. Laing to Head New Innovation Organization in Austin, TX
After 11 years developing and growing commercialization, investment, and business acceleration programs at Philadelphia’s University City Science Center, Christopher Laing, MRCVS, Ph.D. has been tapped to lead the effort to establish a new healthcare-focused innovation zone in Austin, Texas. Dr. Laing will become the first Executive Director at the newly formed Capital City Innovation effective September 1, 2017. He has served as the Vice President, Science & Technology at the Science Center since 2010.
One Health Company balances improving biomedical research and ethical animal testing
The One Health Company, a contract research organization, understands the strong connection between pets and their owners in more ways than one. It is working to make biomedical research more efficient with a business that recognizes the similarities between certain diseases experienced by dogs and humans.
Philly Now a Top 5 City for Life Sciences, Study Says
Professional services and research firm JLL recently released its annual Life Sciences Outlook report, which scores 15 metropolitan areas across the country and Canada on life sciences workforce statistics, funding availability, and other factors.
Circuits, animatronics and a ‘smart beehive’ at Maximilian Lawrence’s ‘Feature Creep’
Artist and well-known time traveler Maximillian Lawrence went back to the future for inspiration. This time around, the result of his time warping was a solo show at the University City Science Center’s Esther Klein Gallery titled “Feature Creep” (a term used to describe the excessive expansion or addition of new features in a software product). The artist, who is an engineering professor at the Science Leadership Academy by day, adopted the term to describe the process of life creeping into a piece of artwork.
What’s Militia Hill Ventures’ take on biotech, cancer therapy investment? (Q&A)
Jane Holmes Hollingsworth is a Philadelphia-based serial healthcare entrepreneur with a couple of successful exits under her belt. Teva Pharmaceuticals snapped up migraine pain patch business NuPathe for $114 million and drug developer Auxilium was sold to Endo Pharmaceuticals in a deal valued at $2.6 billion. Since then she has shifted her focus to biotech investment as cofounder and managing partner of Militia Hill Ventures with Joan Lau. Together they hope to create a self-sustaining entrepreneurial ecosystem in the City of Brotherly Love.
Two New Members Elected to University City Science Center Board of Directors
Two new members were elected to the University City Science Center’s Board of Directors at its annual Shareholders Meeting on June 9, 2017: Jeremy Nowak, President, J Nowak Strategy and Michele Masucci, Ph.D., Vice President for Research Administration at Temple University. The Science Center also announced the election of Glen N. Gaulton and Kenneth L. Kring, and re-election of David P. Holveck and Richard P. Jaffe, as Directors Emeriti.
Former Phillies slugger Ryan Howard really sees a future for himself among entrepreneurs. Last month, we learned that the former National League MVP and World Series champion is officially a partner at SeventySix Capital. Thursday evening, he sat down for the first time before the public as a VC with fellow SeventySix Capital partner Wayne Kimmel and Villanova Law’s Moorad Center for Sports Law director Andrew Brandt.
How to take Philly's place in tech world from 'complacent' to 'buzzy' MORE
In a recent article in Philadelphia magazine, it seems writer John Marchese was trying to light a fire under Philadelphia’s leaders. Marchese investigates the progress Pittsburgh has made in developing cutting-edge technologies such as robotics and autonomous vehicles, transforming itself from a declining manufacturing town into a technology and innovation hub.
Want To Speed Biomedical Research? Do It In Dog Years
Biomedical research takes a long time… Way too long for patients anxiously waiting for treatments that can keep them alive or spare them agony. So, here is an idea. How about switching research’s typical drawn-out, excruciating timeline to dog years. Dog years?